First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses. Association between ...
Sanofi is in the final stages of selling its European generics business, Zentiva, to private equity firm Advent International. The companies have signed a share purchase agreement valued at €1.9 ...
Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular ...
Creditors are ready to provide debt financing in the amount of 3 billion euros as part of the proposed acquisition of the manufacturer of Zentiva generics. This is reported by foreign media. Earlier, ...
Background: The relative superiority of atezolizumab–bevacizumab versus pembrolizumab-lenvatinib in treatment of unresectable hepatocellular carcinoma (HCC) remains uncertain. This study aims to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results